Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report.

Journal of human immunity·2026
Same author

Response to "Defining durability in SCD gene therapy".

Blood advances·2026
Same author

Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in Sickle Cell Disease.

Blood·2026
Same author

Clinical outcomes of lentiviral vector gene therapy for sickle cell disease.

Blood advances·2026
Same author

A blueprint to accelerate rare pediatric gene therapy approvals.

Nature medicine·2026
Same author

Management of medically inoperable low-grade endometrial cancer: patterns of care and outcomes with radiation, brachytherapy, and hormonal therapy.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

Related Experiment Video

Updated: Oct 9, 2025

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

35.6K

Improved lentiviral vector titers from a multi-gene knockout packaging line.

Jiaying Han1, Kevin Tam2, Curtis Tam2

  • 1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.

Molecular Therapy Oncolytics
|December 23, 2021
PubMed
Summary

Researchers enhanced lentiviral vector (LV) production by modifying packaging cells and overexpressing transcription factors. This resulted in significantly higher viral titers, overcoming barriers for gene therapy applications.

Keywords:
CAR-THEK293T cellsgene and cell therapyhemoglobinopathylentiviral vectorpackaging

More Related Videos

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
13:47

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

9.9K
A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells
10:42

A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells

Published on: December 12, 2017

15.6K

Related Experiment Videos

Last Updated: Oct 9, 2025

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

35.6K
Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
13:47

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

9.9K
A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells
10:42

A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells

Published on: December 12, 2017

15.6K

Area of Science:

  • Gene Therapy
  • Molecular Biology
  • Virology

Background:

  • Lentiviral vectors (LVs) are crucial for gene therapy due to efficient genome integration.
  • Production challenges exist for LVs with complex expression cassettes, limiting clinical use.

Purpose of the Study:

  • To enhance lentiviral vector (LV) production titers and infectivity.
  • To identify and overcome host cell restriction factors impeding LV manufacturing.

Main Methods:

  • Knockout of host restriction factors (OAS1, LDLR, PKR) in HEK293T cells to create the CHEDAR cell line.
  • Overexpression of transcription elongation factors (SPT4, SPT5) during vector packaging.

Main Results:

  • Knocking out OAS1 and LDLR individually increased viral titers by approximately 2-fold.
  • The CHEDAR cell line achieved a ~7-fold increase in physical particles, RNA, and vector titers.
  • Overexpressing SPT4 and SPT5 increased titers by ~2-fold.
  • Combined CHEDAR packaging with SPT4/SPT5 overexpression yielded an ~11-fold increase in titers.
  • Improved production of challenging LVs, including those with reverse-oriented internal promoters.

Conclusions:

  • Engineering packaging cell lines and optimizing expression factors can significantly boost LV production.
  • These advancements facilitate the manufacturing of complex LVs for gene therapy.
  • The developed methods offer broad benefits for various gene therapy applications.